STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
Key facts
- Who runs it
- Seelos Therapeutics, Inc.
- Where
- Aurora, Boston, Dallas, Los Angeles, New York, Seattle, and Tampa, United StatesSee the 7 sitesAlso in 7 other countries, 16 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2/3
- People taking part
- 23 people enrolled
- Started
- 3 Jun 2022
- Ended
- 24 Nov 2023
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- SLS-005
- Placebo
- Record updated
- 24 April 2024
- Why it stopped
- This was a business decision due to financial considerations, not based on data related to safety or therapeutic effects.
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Signed informed consent
- Men and women, 18 to 75 years (inclusive) of age
- Clinical diagnosis of SCA3 with documented genetic confirmation
- m-SARA total score ≥ 4 at the screening visit
- m-SARA gait component score ≥ 1 at the screening visit
- Body Mass Index (BMI) between 18 kg/m2 and 35 kg/m2 (inclusive)
- Stable doses of all concomitant medications for at least 30 days prior to the screening visit
- Negative serum beta-human chorionic gonadotropin (ß-hCG) pregnancy result at the screening visit for female participants of childbearing potential
- Willingness to comply with sexual abstinence or contraception guidelines of this study
Who cannot take part
- Current participation in another clinical trial or completed participation in an interventional trial less than 30 days prior to the screening visit (90 days for a biological treatment)
- Prior treatment with SLS-005, any other IV trehalose formulation, or known hypersensitivity to trehalose
- Any hereditary ataxia that is not genetically confirmed to be SCA type 3, or any type of ataxia that is acquired or secondary to another medical condition including but not limited to, alcoholism, head injury, multiple sclerosis, olivopontocerebellar atrophy, multiple system atrophy, or stroke
- Current diagnosis and/or healthcare professional-recommended treatment (medication and/or diet) of diabetes mellitus type 1 or type 2
- History of alcohol or drug abuse within the last 2 years
- Chronic liver disease including Hepatitis B; Hepatitis C unless successful curative treatment is documented; human immunodeficiency virus (HIV) infection
- Any current cardiovascular disease or abnormality on 12-lead ECG at screening that, in the investigator's opinion, is clinically significant and could be a potential safety risk to the participant
- Any current psychiatric, neurological, or cognitive disorder that, in the investigator's opinion, may interfere with the participant's ability to provide informed consent or appropriately complete the study's safety or efficacy assessments
- Any other medical condition or abnormal finding during screening that, in the investigator's opinion, could confound collection or interpretation of safety or efficacy data or be a potential safety risk to the participant
- Hemoglobin A1c (HbA1c) ≥ 6.5% at the screening visit
- Prior history of drug-induced liver injury (DILI) and/or laboratory results at screening that indicate inadequate liver function (e.g., alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyl transferase [GGT] > 2 times the upper limit of normal [x ULN] and/or total bilirubin level > 2 x ULN)
- Laboratory results at screening that indicate inadequate renal function (e.g., estimated creatinine clearance of < 60 mL/min calculated by the Cockcroft and Gault formula)
- A score of 4 on any 1 of the 4 items that comprise the m-SARA
- Pregnant or breastfeeding
- Significant suicide risk as indicated by a "yes" response to question #4 or #5 under Suicidal Ideation in the past 6 months or any "yes" response under Suicidal Behavior in the past 3 years on the Columbia Suicide Severity Rating Scale (C-SSRS) during the screening visit
Where in United States
Also in 7 other countries, 16 sites
- UCHealth Neurosciences Center - Anschutz Medical CampusAurora, United States
- Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC)Boston, United States
- UT Southwestern Medical CenterDallas, United States
- UCLALos Angeles, United States
- Columbia University Medical CenterNew York, United States
- Swedish Neuroscience Specialists - Movement DisordersSeattle, United States
- University of South FloridaTampa, United States
About the trial
What the trial wants to find out
Phase 2b/3 double blind, randomized, placebo-controlled trial to assess safety and efficacy of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of adults with spinocerebellar ataxia).
The 4 groups in the trial
- SLS-005 0.75 g/kg DoseTreatment being tested
SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion). SLS-005 will be administered as a weight-based dose of 0.75 g/kg by IV infusion once a week. For 52 weeks
Treatment: SLS-005
- SLS-005 0.50 g/kg DoseTreatment being tested
SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion). SLS-005 will be administered as a weight-based dose of 0.50 g/kg by IV infusion once a week. For 52 weeks
Treatment: SLS-005
- Placebo volume equivalent to a SLS-005 0.75 g/kg dose calculationPlacebo, for comparison
Placebo (sodium chloride injection, 0.9, USP) will be administered by IV infusion once a week as a weight-based volume equivalent to a SLS-005 0.75 g/kg dose. For 52 weeks
Treatment: Placebo
- Placebo volume equivalent to a SLS-005 0.50 g/kg dose calculationPlacebo, for comparison
Placebo (sodium chloride injection, 0.9, USP) will be administered by IV infusion once a week as a weight-based volume equivalent to a SLS-005 0.50 g/kg dose. For 52 weeks
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Double-blind, Randomized, Placebo Controlled, Trial to Assess Safety and Efficacy of SLS-005 (Trehalose Injection, 90.5 mg/mL for Intravenous Infusion) for the Treatment of Adults With Spinocerebellar Ataxia
- Record updated
- 24 April 2024